[Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback] | ||
England and Wales Court of Appeal (Civil Division) Decisions |
||
You are here: BAILII >> Databases >> England and Wales Court of Appeal (Civil Division) Decisions >> Yeda Research and Development Co Ltd. v Rhone-Poulenc Rorer International Holdings & Anor [2006] EWCA Civ 1094 (31 July 2006) URL: http://www.bailii.org/ew/cases/EWCA/Civ/2006/1094.html Cite as: [2006] EWCA Civ 1094, [2007] Bus LR 1 |
[New search] [Printable RTF version] [Buy ICLR report: [2007] Bus LR 1] [Help]
COURT OF APPEAL (CIVIL DIVISION)
ON APPEAL FROM THE HIGH COURT OF JUSTICE
CHANCERY DIVISION (PATENTS COURT)
The Hon Mr Justice Lewison
CH 2005 APP 0795/0798
Strand, London, WC2A 2LL |
||
B e f o r e :
LORD JUSTICE KEENE
and
LORD JUSTICE JACOB
____________________
Yeda Research and Development Co Ltd |
Appellant |
|
- and - |
||
(1) Rhone-Poulenc Rorer International Holdings Inc (2) ImClone Systems Inc |
Respond-ents |
|
-and- |
||
The Comptroller of Patents Designs and Trademarks |
Intervener |
____________________
Smith Bernal WordWave Limited
190 Fleet Street, London EC4A 2AG
Tel No: 020 7421 4040 Fax No: 020 7831 8838
Official Shorthand Writers to the Court)
for the Appellant
Peter Prescott QC and Andrew Lykiardopoulos (instructed by Bird & Bird)
for the First Respondent
Peter Prescott QC and Michael Tappin (instructed by Milbank, Tweed Hadley
& McCloy LLP) for the Second Respondent
Michael Edenborough (instructed by the Treasury Solicitor) for the Intervener
____________________
Crown Copyright ©
Lord Justice Jacob (giving the first judgment at the invitation of the Master of the Rolls):
Background
"[1] The patent in suit relates to therapeutic compositions containing certain monoclonal antibodies in combination with anti-neoplastic drugs. The antibodies are specific to a human receptor for epidermal growth factor ("EGF") and can inhibit the growth of human tumour cells that express human EGF receptors by binding to the extra-cellular domain of the receptors to form an antigen-antibody complex. The invention rests on the discovery that the combined treatment is more efficient than the use of either agent by itself because it kills the cancer cells (a cytotoxic effect) rather than merely prevents them from replicating (a cytostatic effect). It also allows the use of lower amounts of toxic or sub-toxic anti-neoplastic drugs."
"the s.8 jurisdiction, although based on an entitlement, is free-standing with its own remedies. The Comptroller is given a very wide discretion once a finding of entitlement is made: he can order licences, cross-licences, the power to sub-licence and amendment of the patent, all to fit the justice of the case see s.8(2). There is no need for an all-or-nothing solution. So if B, having taken A's idea, genuinely adds inventive material of his own, there is ample power to produce an equitable and fair commercial solution."
"Where a person refers a question relating to an invention . the comptroller may, without prejudice to the generality of subsection (1) above and subject to subsection (6) below -
..
(d) make an order transferring or granting any licence or other right in or under the application
And also that s.37(2) (dealing with a post-grant entitlement reference) says:
(2) Without prejudice to the generality of subsection (1) above, an order under that subsection may contain provision -
..
(c) granting any licence or other right in or under the patent;
"The Referrer hereby refers to the Comptroller the following questions:
i) whether it should be joint proprietor of [the patent] (section 37(1)(a));
ii) whether [certain named persons, called "the Weizmann inventors"] should be named as co-inventors of the Patent (section 37(1)(c))."
"37.-(1) After a patent has been granted for an invention any person having or claiming a proprietary interest in or under the patent may refer to the comptroller the question -"
(a) who is or are the true proprietor or proprietors of the patent,
(b) whether the patent should have been granted to the person or persons to whom it was granted, or
(c) whether any right in or under the patent should be transferred or granted to any other person or persons;
and the comptroller shall determine the question and make such order as he thinks fit to give effect to the determination.
(5) On any such reference no order shall be made under this section transferring the patent to which the reference relates on the ground that the patent was granted to a person not so entitled, and no order shall be made under subsection (4) above on that ground, if the reference was made after the end of the period of two years beginning with the date of the grant, unless it is shown that any person registered as a proprietor of the patent knew at the time of the grant or, as the case may be, of the transfer of the patent to him that he was not entitled to the patent.
"questions to the Comptroller
The Referrer hereby refers to the Comptroller the following questions:
(i) whether it should be sole proprietor or, in the alternative, joint proprietor of [the Patent] (section 37(1)(a));and
(ii) whether the Patent should have been granted to Rorer (section 37(1)(b));
(iii) whether all or any of the rights in or under the Patent (including any licence) should be transferred or granted to the Referrer (section 37(1)(c)); and
(ii)(iv) whether [the "Weizmann Inventors"] should be named as inventors or, in the alternative, co-inventors of the Patent (section 37(1)(c))."
"The Referrer requests that the Comptroller orderthat:
(i) that the Patent be transferred into sole ownership of the Referrer or, in the alternative, co-ownership of Rorer and the Referrer, such ownership or co-ownership to take effect as though the Patent had originally been granted to the Referrer alone or, in the alternative, to both co-owners;
(ii) that thepPatent be amended so as to name the Weizmann Inventors as inventors or, in the alternative, co-inventors;and
(iii) that any Supplementary Protection Certificate(s) granted under the Patent be transferred into the sole ownership of the Referrer or, in the alternative, co-ownership of Rorer and the Referrer;
(iii)(iv) that Rorer do everything within its control to effect the necessary changes to the Patent and the Patent Register to give effect to the change in proprietorship and inventorship.;
(v) such further or other order as shall be appropriate in relation to any licence under the Patent, including, without limitation, an order for an account to be taken of all licence fees paid under any such licence and an order to transfer all of these monies or, in the alternative, a proportion of these monies, to the Referrer, with interest thereon at an appropriate rate to be determined by the Comptroller;
(vi) such further or other order to enable the Referrer fully to exploit or, in the alternative, equally to exploit the Patent, including, without limitation, the right to grant licences without reference to Rorer or ImClone;
(vii) that Rorer and/or ImClone do pay the Referrer's costs, to be assessed if not agreed; and
(viii) further or other relief."
"(7) Whereas by a resolution made on the signature of the Community Patent Convention the governments of the member states of the European Economic Community resolved to adjust their laws relating to patents so as (among other things) to bring those laws into conformity with the corresponding provisions of the European Patent Convention, the Community Patent Convention and the Patent Co-Operation Treaty, it is hereby declared that the following provisions of this Act, that is to say, sections 1(1) to (4), 2 to 6, 14(3), (5) and (6), 37(5), 54, 60, 69, 72(1) and (2), 74(4), 82, 83, 100 and 125, are so framed as to have, as nearly as practicable, the same effects in the United Kingdom as the corresponding provisions of the European Patent Convention, the Community Patent Convention and the Patent Co-operation Treaty have in the territories to which those Conventions apply. "
Customs at [6] "One wonders why a draftsman implementing a Directive or other international treaty provides his own elaborate language attempting to set out what the implemented law is supposed to be. I have commented on the unnecessary complications that this process causes in intellectual property. For instance in Beloit Technologies v Valmet Paper [1995] RPC 705 at p.731 I said:
' it helps no-one for the Parliamentary draftsman to re-write matter in a treaty or convention (or EU directive for that matter) which is to be implemented in the United Kingdom. If the language of the basic document is obscure or less than complete it makes things worse if the Parliamentary draftsman tries to "clarify" it in some other words. Where he does, he simply causes extra complications (and therefore legal uncertainty and costs) .... The point at which obscurities should be avoided is in the underlying international document. If they are unfortunately there, it is too late for our Parliamentary draftsman to help and the problem must be left for industry to pay for in the courts. The particular question here is a typical example of what could be avoided by simply adopting the language of the underlying document as it stands.'"
Markem [94] "Before doing so, we begin by what must be the rational way to approach this [i.e. the Patents Act 1977], whatever section is under consideration. Parts of it are intended to implement the European Patent Convention of 1972. In a peculiarly cack-handed way the draftsman chose to re-number and re-write some of these and then say, in s.130(7) in effect that his re-writing does not count that the relevant provision is "so framed as to have, as nearly as practicable, the same effect in the UK as it has in the EPC". No one has ever identified any difference in meaning between a 1977 Act provision and the meaning of a corresponding provision of the EPC and we do not suppose anyone ever will."
"[127] As a matter of ordinary language, given that the Convention has not been ratified, and has never come into effect, there are no "territories to which the Convention appl[ies]." There is, therefore, in my judgment, real force in the point that unless and until the Convention is brought into force, it is scarcely possible to talk about a provision such as Art.56(1) having "the same effects" in the sense for which Stolt contend, namely the consequences set out in Art.33, as Art.56(1) or its equivalent has "in the territories to which [the] Convention app[lies]", in circumstances where the Convention does not apply in any territory at all.
In this connection, it should be mentioned that the effect of Art.6(2) of the Convention (mirroring Art.98 of the 1975 form) is that it can only come into effect when all the signatory states have ratified it.
I appreciate that the point found no favour with Jacob J. on the basis that s.130(7) "is an interpretation section", and that the same view appears to have been taken by this court in Kimberly-Clark Worldwide Inc v Procter & Gamble Ltd [2000] R.P.C. 422 and Menashe Business Mercantile Ltd v William Hill Organisation Ltd [2003] RPC 31. However, it appears to me that, particularly if the word "effects" is given the wide meaning for which Stolt contends in the present case, the closing words of s.130(7) indicate that, so long as the Convention is not in force, the subsection may well not apply. However, if the narrower meaning, which I believe to be correct, is given to the word "effects", then it would appear to me to strengthen the contrary view reached by Jacob J, and, indeed, apparently assumed to be correct by the Court of Appeal. I should add that it appears clear that there was no argument on the point in either of the two cases before the Court of Appeal.
In all the circumstances, I do not consider that we should decide the second ground raised by Mr Miller for rejecting Stolt's case based on the Convention. It is unnecessary to decide it, and the reason I have discussed it is to only explain why it impressed me rather.
"considerable force in the contention of Mr Miller that as there is no territory to which the CPC applies, s.130(7) does not in this respect have application"
"(1) A reference under s.37(1) shall be made on Patents Form 2/77 and shall be accompanied by a copy thereof and a statement in duplicate setting out fully the nature of the question, the facts upon which the person making the reference relies and the order which he is seeking."
"I do not think it is right to divide up the claim for an invention which consists of a combination of elements and then to seek to identify who contributed which element. I think the inquiry is more fundamental than that. One must seek to identify who in substance made the combination. Who was responsible for the inventive concept, namely the combination? That was solely Mr Z. It was his idea which turned a useless collection of elements into something which would work. The patent, as I have said already, is really about the joint. The remainder of the elements of the claim, although necessary, are peripheral."
Robert Walker LJ said this at p. 449:
"I cannot entirely agree with the judge's approach in the passage of his judgment (at 706) which I have already set out. I am not inclined to think that the invention was a "combination" of elements. Mr Z saw Mr X's drawing (at a meeting at which Mr X was not present) and replaced one type of joint (intended to produce a labyrinthine effect) with another type (a key-joint intended to produce distribution of blast pressure, including rebound pressure). Mr X's drawing of the joint was not so much useless as directed at a different objective. Nevertheless I feel no doubt that the judge was correct in his conclusion."
"One of the Rorer Inventors, Dr Schlessinger, provided to the Weizmann Inventors monoclonal antibodies to the EGF receptor which are referred to in the Patent as '108' and '96'"
It goes on to allege that the "relevant practical work using these antibodies" was done by the Weizmann inventors. That is not enough to exclude Dr Schlessinger's contribution as being inventive. Suggesting what is to be tested may indeed lie at the heart of an invention, the testing itself being a matter of what is routine. What the true position is will depend on the detailed facts. For present purposes it is sufficient to say that the unamended statement does not disclose a case of sole inventorship. It accepts and proceeds on the basis that Dr Schlessinger's contribution was inventive.
" a person infringes a patent if .. he does any of the following things in the UK without the consent of the proprietor "
But a co-proprietor has no rights as against any other co-proprietor. This is made explicit by s.36(2):
"(2) Where two or more persons are proprietors of a patent, then, subject to the provisions of this section and subject to any agreement to the contrary -
(a) each of them shall be entitled, by himself or his agents, to do in respect of the invention concerned, for his own benefit and without the consent of or the need to account to the other or others, any act which would apart from this subsection and section 55 below, amount to an infringement of the patent concerned"
"A Community patent shall confer on its proprietor the right to prevent all third parties not having his consent from "
A co-proprietor is simply not a third party and so no right is given against him.
"PART 11. SUBSTANTIVE PATENT LAW
Chapter I. Right to the Community patent
ARTICLE 23
Claiming the right to the Community patent
1. If a Community patent has been granted to a person who is not entitled to it under Article 60(1) of the European Patent Convention, the person entitled to it under that provision may, without prejudice to any other remedy which may be open to him, claim to have the patent transferred to him.
2. Where a person is entitled to only part of the Community patent, that person may, in accordance with paragraph 1, claim to be made a joint proprietor.
3. Legal proceedings in respect of the rights specified in paragraphs 1 and 2 may be instituted only within a period of not more than two years after the date on which the European Patent Bulletin mentions the grant of the European patent. This provision shall not apply if the proprietor of the patent knew, at the time when the patent was granted or transferred to him, that he was not entitled to the patent.
4. The fact that legal proceedings have been instituted shall be entered in the Register of Community Patents. Entry shall also be made of the final decision in, or of any other termination of, the proceedings.
ARTICLE 24
Effect of change of proprietorship
1. Where there is a complete change of proprietorship of a Community patent as a result of legal proceedings under Article 23, licences and other rights shall lapse upon the registration of the person entitled to the patent in the Register of Community Patents.
2. If, before the institution of legal proceedings has been registered,
(a) The proprietor of the patent has used the invention within the territory of any of the Contracting States or made effective and serious preparations to do so, or
(b) a licensee of the patent has obtained his licence and has used the invention within the territory of any of the Contracting States or made effective and serious preparations to do so,
he may continue such use provided that he requests a non-exclusive licence of the patent from the new proprietor whose name is entered in the Register of Community Patents. Such request must be made within the period prescribed in the Implementing Regulations. The licence shall be granted for a reasonable period and upon reasonable terms.
3. Paragraph 2 shall not apply if the proprietor of the patent or the licensee, as the case may be, was acting in bad faith at the time when he began to use the invention or to make preparations to do so."
"1. The right to a European patent shall belong to the inventor or his successor in title. If the inventor is an employee the right to the European patent shall be determined in accordance with the law of the State in which the employee is mainly employed; if the State in which the employee is mainly employed cannot be determined, the law to be applied shall be that of the State in which the employer has his place of business to which the employee is attached."
"In the interests of legal certainty, Article 23(3) CPC provides that legal proceedings in respect of transfer and joint proprietorship can only be instituted within two years of publication of the mention of grant of the patent. Any legal proceedings will be time-barred after this period, which means that upon its expiry not only can the person entitled no longer take legal action to claim a right to the patent, but he will also be precluded from applying for the patent to be revoked on the grounds that the proprietor is not entitled to it.
This time limit will not apply, however, if the proprietor knew, at the time when the patent was granted or transferred from a third party, that he was not entitled to become proprietor of the patent. If he learns only later that he is not entitled, this will not affect the time limit. This solution, giving precedence to legal certainty, requires actual knowledge of the lack of entitlement at the time of grant (or of acquisition of the patent by transfer). A proprietor not entitled to a patent may invoke the two-year time even if he was seriously at fault in failing to establish the position."
"92. The amended claims are new claims both for the reasons given by the Hearing Officer and also because in my judgment that is implicit in Article 23 of the CPC. The claims based on breach of confidence and employment rights are also new claims in the sense of raising wholly new causes of action. If, as I consider, Rorer's defence of limitation remains available, there is no useful purpose in allowing the amendments.
Lord Justice Keene:
Sir Anthony Clarke, MR: